Clinical Trial Detail

NCT ID NCT03258554
Title Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

head and neck squamous cell carcinoma

Therapies

Cetuximab

Durvalumab

Age Groups: adult senior

No variant requirements are available.